59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trialN. Girard, M-J. Ahn, Ria Cornelissen et al.|ESMO Open|2024Cited by 5
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01Akin Atmaca, Christian Schumann, Myung‐Ju Ahn et al.|Pneumologie|2024Cited by 3